Who
Brian S. Posner
Director
Company insider
Files Form 4 as: Director, Dyne Therapeutics; Director, Arch Capital Group; Director, Biogen; Director, Bioverativ; Director, BG Medicine; Director, Anadys Pharmaceuticals; Officer of the Adviser, LMP Capital and Income Fund.
In numbers
- Trades disclosed
- 140
- Buys
- 24
- Sells
- 18
- Bought
- $1.7M
- Sold
- $8.4M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 11 Oct 2006
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $40K2,500 at $16.00 | filing |
| 8 Jun 2026filed 9 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K2,000 at $16.94 | filing |
| 8 Jun 2026filed 9 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K2,000 at $16.94 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K2,500 at $17.48 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K2,500 at $17.48 | filing |
| 3 Jun 2026filed 4 Jun 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Sold | $59K3,000 at $19.66 | filing |
| 3 Jun 2026filed 4 Jun 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Sold | $59K3,000 at $19.66 | filing |
| 26 May 2026filed 28 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $36K2,000 at $18.21 | filing |
| 26 May 2026filed 28 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $36K2,000 at $18.21 | filing |
| 20 May 2026filed 22 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $43K2,500 at $17.12 | filing |
| 20 May 2026filed 22 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $43K2,500 at $17.12 | filing |
| 11 May 2026filed 12 May 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Sold | $34K2,000 at $17.14 | filing |
| 11 May 2026filed 12 May 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Sold | $34K2,000 at $17.14 | filing |
| 5 May 2026filed 7 May 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Code A | —2,071 | filing |
| 5 May 2026filed 7 May 2026 | ACGL Arch Capital GroupInsurance | SEC FORM 4 Code A | —2,071 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K2,000 at $17.08 | filing |
| 30 Mar 2026filed 1 Apr 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K2,000 at $17.08 | filing |
| 11 Mar 2026filed 13 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K2,000 at $19.35 | filing |
News
Arch Capital Group Ltd. (NASDAQ:ACGLN) Sees Significant Decrease in Short InterestACGL · tickerreport.com · 14 Oct 2026JPMorgan Chase & Co. Cuts Arch Capital Group (NASDAQ:ACGL) Price Target to $113.00ACGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Brian S. Posner; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.